535 related articles for article (PubMed ID: 36871783)
1. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
2. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
3. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
4. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
6. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
8. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J; Chen X; Lu A; Liang C
Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
12. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
Tamatam R; Shin D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
15. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
17. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
Xie H; Zhang C
Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
[TBL] [Abstract][Full Text] [Related]
18. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications.
Li Q; Zhou L; Qin S; Huang Z; Li B; Liu R; Yang M; Nice EC; Zhu H; Huang C
Eur J Med Chem; 2023 Sep; 257():115447. PubMed ID: 37229829
[TBL] [Abstract][Full Text] [Related]
20. PROTACS: A technology with a gold rush-like atmosphere.
Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
